Haploidentical Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Case Report First Experience

Authors

  • Aleksandra Pivkova-Veljanovska University Clinic for Hematology https://orcid.org/0000-0002-4096-4686
  • Irina Panovska-Stavridis University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Lazar Chadievski University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Sanja Trajkova University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Marija Popova-Labachevska University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Tara Mojsovska University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Simona Stojanoska University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Nevenka Ridova University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Svetlana Krstevska-Balkanov University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Zlate Stojanoski University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia
  • Dejan Spasovski University Clinic for Rheumatology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia https://orcid.org/0000-0002-9144-0524
  • Radica Grubovic-Rastvorceva Institute for Transfusion Medicine, Skopje, Republic of Macedonia https://orcid.org/0000-0002-4885-3323
  • Borce Georgievski University Clinic for Hematology, BMT Unit, Medical Faculty, University “St. Cyril and Methodious”, Skopje, Republic of Macedonia

DOI:

https://doi.org/10.3889/oamjms.2021.7542

Keywords:

Haploidenthical transplantation, Myelodysplastic syndrome, Survival

Abstract

 

BACKGROUND: Allogeneic stem cell transplantation (ASCT) is a potentially curative therapeutic approach in patients with intermediate and high-risk myelodysplastic syndrome (MDS). If a family sibling or unrelated donor is not available mismatched donors are viable option for young patients with no comorbidities. The aim of this case presentation was to evaluate our first experience with haploidentical transplantation for this indication.

CASE PRESENTATION: We present a case of 50 years male patient with myelodysplastic syndrome (MDS) diagnosed at University Clinic for hematology, Skopje, North Macedonia. Patient was scored in IPSS -R as high risk patient. He was referred for HLA DNA typing of family siblings and since he didn’t have identical sibling and unrelated donor, he was referred to continue treatment with haploidentical stem cell transplantation. He received Flu Bu conditioning and PTCY, cyclosporine and MMF for GVHD prophylaxis. Peripheral blood stem cells (PBSC) from his mismatched brother were infused in the amount of CD34=5.8x106/kg. He experienced prolonged engraftment, severe infective bacterial infections and CMV reactivation with clinical manifestation of CMV colitis. He was successfully treated with antiviral drug and completely resolved. His bone marrow analysis showed complete remission and chimerism evaluation revealed high donor engraftment. Patient is now +34 months post transplant in complete remission.

CONCLUSION: The use of a mismatched donor increases the risk of NRM, but there is also evidence to suggest that an haploidentical donor is a valid choice, as general outcome appears to be at least similar to MUD.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Duarte RF, Myriam L, Peter B, Grzegorz W, Chiara B, Ch C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525-52. https://doi.org/10.1038/s41409-019-0516-2 PMid:30953028 DOI: https://doi.org/10.1038/s41409-019-0516-2

Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, et al. Haploidentical transplant in patients with myelodysplastic syndrome. Blood Adv. 2017;1(22):1876-83. https://doi.org/10.1182/bloodadvances.2017007146 PMid:29296834 DOI: https://doi.org/10.1182/bloodadvances.2017007146

Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European society for blood and marrow transplantation (EBMT) Consensus guidelines for the detection and treatment of donorspecific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(5):521-34. https://doi.org/10.1038/s41409-017-0062-8 PMid:29335625 DOI: https://doi.org/10.1038/s41409-017-0062-8

Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in china-recommendations from the Chinese society of hematology. J Hematol Oncol. 2018;11(1):33. https://doi.org/10.1186/s13045-018-0564-x PMid:29495966 DOI: https://doi.org/10.1186/s13045-018-0564-x

Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: An update. Bone Marrow Transplant. 2015;50 Suppl 2:S37-9. https://doi.org/10.1038/bmt.2015.93 PMid:26039205 DOI: https://doi.org/10.1038/bmt.2015.93

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65. https://doi.org/10.1182/blood-2012-03-420489 PMid:22740453 DOI: https://doi.org/10.1182/blood-2012-03-420489

Ades L, Itzykson PF, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239-52. https://doi.org/10.1016/S0140-6736(13)61901-7 PMid:24656536 DOI: https://doi.org/10.1016/S0140-6736(13)61901-7

Villar S, Robin M. Allogeneic stem cell transplantation for MDS. Hematology. 2021;2:545-55. https://doi.org/10.3390/hemato2030034 DOI: https://doi.org/10.3390/hemato2030034

Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260-72. https://doi.org/10.1016/S1473-3099(19)30107-0 PMid:31153807 DOI: https://doi.org/10.1016/S1473-3099(19)30107-0

Downloads

Published

2021-11-23

How to Cite

1.
Pivkova-Veljanovska A, Panovska-Stavridis I, Chadievski L, Trajkova S, Popova-Labachevska M, Mojsovska T, Stojanoska S, Ridova N, Krstevska-Balkanov S, Stojanoski Z, Spasovski D, Grubovic-Rastvorceva R, Georgievski B. Haploidentical Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Case Report First Experience. Open Access Maced J Med Sci [Internet]. 2021 Nov. 23 [cited 2024 Mar. 29];9(C):250-3. Available from: https://oamjms.eu/index.php/mjms/article/view/7542

Issue

Section

Case Report in Internal Medicine

Categories

Most read articles by the same author(s)